Brief: Pepgen Announces Clinical Hold In The U.S. On Ind Application To Initiate Connect2-Edo51 Phase 2 Study
16/12/2024 13:38
Dec 16 (Reuters) - PepGen Inc PEPG.O :
* PEPGEN ANNOUNCES CLINICAL HOLD IN THE U.S. ON IND
APPLICATION TO
INITIATE CONNECT2-EDO51 PHASE 2 STUDY OF PGN-EDO51 FOR DUCHENNE
MUSCULAR DYSTROPHY
* CONTINUES TO ADVANCE PGN-EDO51 IN CONNECT1-EDO51, WITH 10
MG/KG
COHORT NOW FULLY ENROLLED
Source text: ID:nBw6HxDTNa
Further company coverage: PEPG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PepGen
See all newsDyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
PepGen Inc. reports results for the quarter ended June 30 - Earnings Summary
PepGen Q2 net loss narrows as expenses fall
Brief: PepGen Q2 EPS USD -0.26
PepGen Inc expected to post a loss of 29 cents a share - Earnings Preview